Navigation Links
New Data Showed Type 2 Diabetes Patients Experienced Greater Blood Sugar Reductions when Treated with ACTOplus met(R) (pioglitazone HCl and metformin HCl) as Initial Therapy Compared to Either Component Alone
Date:10/14/2009

DEERFIELD, Ill., Oct. 14 /PRNewswire/ -- A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone. Safety and tolerability of ACTOplus met therapy were evaluated by rate of drug discontinuation and treatment-emergent adverse events.

"Diabetes is a progressive and chronic condition, which requires continued monitoring by a patient and physician. In addition to diet and exercise, patients often need to take multiple medications to help them manage their glucose control," said Robert Spanheimer, M.D., vice president of medical and scientific affairs, Takeda Pharmaceuticals North America, Inc. "We are pleased to see that this study was successful in meeting its intended endpoints. A greater number of patients reached the blood sugar target of less than 7 percent, as recommended by the American Diabetes Association, using combination therapy as initial treatment compared with either single treatment alone."

Upon completion of the study, all treatment groups achieved statistically significant HbA1c reductions (p<0.001) from a baseline HbA1c of 8.7, and the greatest decrease was observed in patients treated with ACTOplus met (15 mg/850 mg twice daily) (-1.83 percent versus 0.99 percent and 0.96 percent with ACTOS® (pioglitazone HCl) (15 mg twice daily) or metformin (850 mg twice daily), respectively). The endpoint responder rates were higher in the ACTOplus met group, with 64 percent of patients reaching HbA1c goal of less than or equal to 7 percent compared to ACTOS (46 percent) or metformin (39 percent) alone.

The overall treatment-emergent adverse events were 50.7 perc
'/>"/>

SOURCE Takeda Pharmaceuticals North America
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Bayers Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients
2. Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
3. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
4. New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients Blood Sugar
5. Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
6. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
7. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
8. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
9. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
10. Three Studies Presented at the American Society of Hematology Annual Meeting Showed Response to Treatment with Campath(R) in Patients with High-Risk CLL
11. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 Thoratec Corporation (NASDAQ: ... mechanical circulatory support therapies to save, support and restore ... the 2014 Morgan Stanley Global Healthcare Conference on Wednesday, ... President and Chief Executive Officer, will provide an update ... Time (9:55 a.m., Pacific Daylight Time).   ...
(Date:8/29/2014)... 29, 2014 Research and Markets  has announced ... Insight 2014" report to their offering. ... one of the largest segments of pharmaceuticals industry. The numbers ... the available therapies were unable to meet the market requirements. ... for CNS disorder, especially over the past two decades. The ...
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... July 27, 2011 Reportlinker.com announces that ... in its catalogue: India ... Till 2016 http://www.reportlinker.com/p0575381/India-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital ...
... 26, 2011 Symmetry Medical Inc. (NYSE: SMA ... orthopaedic device industry and other medical markets, announced today that ... period ending July 2, 2011 before the market opens on ... conference call at 8:00 a.m. ET on Thursday, August 4, ...
Cached Medicine Technology:India Cardiac Catheters and Guidewires - Market Trends Till 2016 2India Cardiac Catheters and Guidewires - Market Trends Till 2016 3Symmetry Medical to Report Second Quarter 2011 Financial Results on August 4, 2011 2
(Date:8/31/2014)... 01, 2014 In order to celebrate the ... announced its latest designs and launched a big promotion. Now, ... , All the company’s new cars are made with ... for the global customers. As a matter of fact, it ... items. Those who are in need of cheap cars can ...
(Date:8/31/2014)... 2014 LabDoor.com tests the purity and ... According to their website, “We buy products in the ... stores and online sites. No manufacturer-supplied samples are permitted ... Healthy with LabDoor,” a recent study was performed on ... in the United States for Vitamin D3 content, heavy ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 In the ... of states have proposed legislation to require mandatory labeling ... can make informed purchasing decisions that affect their own ... industry leader advocating for stringent measures to eliminate GMOs ... its “Information, Communication, Engagement” (I.C.E.) initiative with the objective ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 Twin to twin ... Aiden and Blake Colp before they were born, but an innovative ... gave them the chance at life. , Now, their parents ... the life-saving fetal surgery option available in St. Louis at the ... nights at Market Pub House (6655 Delmar Blvd, St Louis, ...
(Date:8/31/2014)... Tickets for Brazil vs. Ecuador at MetLife Stadium ... is great news for diehard soccer fans who would have loved ... delight of soccer fans in the Tri-State area these two international ... 9th. , MetLife Stadium is the home field for ... National Football League. The venue opened in 2010 and has already ...
Breaking Medicine News(10 mins):Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 2Health News:After a Rare Diagnosis Threatened Their Boys’ Lives, Parents Build Awareness About TTTS and Fetal Surgery Options at The SSM St. Louis Fetal Care Institute. 3Health News:Brazil vs. Ecuador Tickets MetLife Stadium: Ticket Down Slashes Ticket Prices on Ecuador vs. Brazil Tickets in East Rutherford, NJ at the MetLife Stadium 2
... The bastion of the diagnostic company, Medlab, seems to ... an Australian Company, which has been the recipient of ... by the district health boards in Auckland, scheduled to ... Australasia Royal College of Pathologists find themselves in a ...
... have known that a woman’s natural hormone levels can ... study from the University of Southern California// (USC)// has ... women varies by ethnicity and race, and may explain ... study appears in the October issue of Cancer Epidemiology, ...
... index (BMI) received lower scores on cognitive tests than middle-aged ... the// October 10, 2006, issue of Neurology, the scientific journal ... investigated the relationships between BMI and cognitive function in 2,223 ... four cognitive tests. The participants, who were between the ages ...
... to assist HIV infection, may aid the fight against malaria, ... already in use to combat HIV is need of the ... new genre of anti-malarial drugs. ,This is indeed ... and also befalling the HIV afflicted lot with uncanny regularity. ...
... holding a world of cures tucked in its many ... right// ingredients needed to nip breast cancer cells in ... discovered in the compound called indole-3-carbinol (I3C), found in ... cancer cells when combined with conventional chemotherapy drugs. By ...
... change in Egypt in spite of the extensive awareness campaigns, ... flu, since May.// ,A woman in the northern ... aggressive form of bird flu virus, H5N1. ,According ... was suffering from high fever and shortness of breath. She ...
Cached Medicine News:Health News:Ethnic Variations in Hormone Levels May Cause Differences in Breast Cancer Risk 2Health News:High BMI Tied to Poor Cognitive Function in Middle-Aged Adults 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: